• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet posts Q3 sales beat, remains on track for Omnipod 5 clearance

November 5, 2021 By Sean Whooley

Insulet (NSDQ:PODD) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast.

The Acton, Massachusetts-based tubeless insulin pump technology developer posted profits of $12.6 million, or 18¢ per share, on sales of $275.6 million for the three months ended Sept. 30, 2021, for an 8.6% bottom-line gain on sales growth of 17.8%.

Adjusted to exclude one-time items, earnings per share were 18¢, 2¢ behind Wall Street, where analysts were looking for sales of $273.2 million.

“Our third-quarter results reflect the growing power of Omnipod. We are driving global new customer starts, have momentum across our business, and are advancing exciting new innovations,” Insulet President & CEO Shacey Petrovic said in a news release. “We continue to share compelling clinical data that demonstrates the improved outcomes and quality of life Omnipod offers to people of all ages.

“We remain on track for Omnipod 5 clearance later this year and cannot wait to bring this transformational product to market and further our mission of improving the lives of people with diabetes.”

 

READ: An interview with Shacey Petrovic, talking Omnipod 5 and its expected launch

 

Insulet increased the bottom line of its revenue guidance, updating the previous projections of between 16% growth and 20% growth to between 18% growth and 20% growth.

PODD shares were up 0.4% at $302.77 per share in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.1%.

BTIG analyst Marie Thibault wrote in a report that high expectations for Insulet may mean shares trade slightly off today, but the performance in the third quarter was rather straightforward.

“We like PODD’s consistent performance, insulated revenue model, and are bullish on Omnipod 5 but believe investors are already assuming a strong U.S. launch and robust 2022 sales growth,” Thibault said.

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS